SOM Biotech Concludes 2020 with Advanced and Robust Pipeline
SOM Biotech, a biopharmaceutical company specialising in the repositioning of existing drugs for the treatment...
Programme SOM0208 for the Treatment of Niemann–Pick Type C Disease
SOM0208 is a small molecule for the treatment of Niemann–Pick C disease.
Niemann–Pick type C is a lysosomal storage disorder caused by defects in the intracellular transport and metabolism of cholesterol and glycolipids. The disease has a broad clinical spectrum. Affected individuals may have enlargement of the spleen (splenomegaly) and liver (hepatomegaly), or enlarged spleen or liver combined (hepatosplenomegaly), but this finding may be absent in later onset cases. Prolonged jaundice or elevated bilirubin can present at birth.
More About This Company
Covid-19 Therapeutics
The current Covid-19 pandemic situation has shown that repurposing drugs can be crucial for delivering...
SOM Biotech Announces Poster Presentation on the Repurposing of Eravacycline for the Treatment of SARS-CoV-2
SOM Biotech, a biopharmaceutical company specialising in the repositioning of existing drugs for the treatment...
SOM Biotech Announces in Vitro Confirmation of Drug Candidates for Covid-19 in Collaboration with Ewha Woman’s University
SOM Biotech, a clinical-stage drug discovery and development company, announces the in vitro validation of...